

Sheet 1 of 2


FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. G-1265I	Serial No 10/023,132
	Applicants Jiban Kumar Chakrabarti et al.	
	Filing Date December 18, 2001	Group 1624

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures	
		Number-Kind Code <sup>2</sup> (if known)			class	subclass
BC	AA	US 4,115,574	09-19-1978	Chakrabarti et al.	424	250
BC	AB	US 5,051,516	09-24-1991	Chakrabarti et al.	548	194
BC	AC	US 5,605,897	2-25-1997	Beasley, Jr. et al.	514	220
BC	AD	US 5,627,178	05-06-1997	Chakrabarti et al.	514	220
BC	AE	US 5,817,655	10-06-1998	Chakrabarti et al.	514	220
BC	AF	US 5,817,656	10-06-1998	Beasley, Jr. et al.	514	220
BC	AG	US 5,817,657	10-06-1998	Beasley, Jr. et al.	514	220

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	BA					
	BB					
	BC					
	BD					
	BE					
	BF					
	BG					
	BH					
	BI					



FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. G-12651	Serial No 10/023,132
	Applicants Jiban Kumar Chakrabarti et al.	
	Filing Date December 18, 2001	Group 1624

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T <sup>6</sup>
BC	CA	C.A. ALTAR, ET AL., Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists, Naunyn-Schmiedeberg's Arch. Pharmacol, 1988, 162-168, 338	
BC	CB	H. R. SULLIVAN, ET AL., <i>In Vitro</i> Thiomethylation - Studies with Flumetzapine, Drug Metabolism and Disposition, 1985, 276-278, Vol. 13, No. 3	
BC	CC	H. G. SCHAUZU ET AL., A Free-Wilson Study of 4-Piperazinyl-10H-thienobenzodiazepine Analogues, Pharmazie, 1983, H 8, 38	
BC	CD	JIBAN K. CHAKRABARTI ET AL., 4-Piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as Potential Neuroleptics, J. Med. Chem., 1980, 878-884, 23	
BC	CE	JIBAN K. CHAKRABARTI ET AL., 10-Piperazinyl-4H-thieno[3,2-b][1,5]- and -[3,4-b][1,5]benzodiazepines as Potential Neuroleptics, J. Med. Chem., 1980, 884-889, 23	
BC	CF	JIBAN K. CHAKRABARTI ET AL., Effects of Conformationally Restricted 4-Piperazinyl-10H-thienobenzodiazepine Neuroleptics on Central Dopaminergic and Cholinergic Systems, J. Med. Chem., 1982, 1133-1140, 25	
BC	CG	JIBAN K. CHAKRABARTI ET AL., Synthesis and Pharmacological Evaluation of CNS Activities of [1,2,3]Triazolo[4,5-b][1,5]-, Imidazolo[4,5-b][1,5]-, and Pyrido[2,3-b][1,5]benzodiazepines. 10-Piperazinyl-4H-1,2,3-Triazolo[4,5-b][1,5]benzodiazepines with Neuroleptic Activity, J. Med. Chem., 1989, 2375-2381, 32	
BC	CH	JIBAN K. CHAKRABARTI ET AL., Synthesis and Pharmacological Evaluation of a Series of 4-Piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as Potential Anxiolytics, J. Med. Chem., 1989, 2573-2582, 32	
	CI	Lilly's Post-Trial Brief	
	CJ	Lilly's Motion for Leave to File Attached Supplemental Post-Trial Brief	
	CK	Defendant Dr. Reddy's Laboratories, Ltd.'s Notice of Filing Corrected Post-Trial Brief, Findings of Fact and Conclusions of Law	
	CL	Dr. Reddy's Laboratories, Ltd.'s Corrected Post-Trial Brief	
	CM	Zenith's Post-Trial Brief	
	CN	Zenith's Post-Trial Reply Brief	
Examiner Signature	Brenda Coleman		Date Considered July 27, 2005

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.